Vaccinex ( (VCNX) ) has released a notification of late filing.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Vaccinex, Inc., a biotechnology company, has announced a delay in filing its Form 10-K (Yearly Report) for the financial period ending December 31, 2024. The primary reason for the delay is the company’s difficulty in completing its financial statements for the year, which could not be resolved without unreasonable effort or expense. Vaccinex expects to file the report within the 15-day extension period allowed under Rule 12b-25. The company does not anticipate any significant changes in its financial results compared to the previous fiscal year. Vaccinex remains committed to compliance and has ensured all other required reports have been filed. The notification was signed by Jill Sanchez, the Chief Financial Officer.
More about Vaccinex
YTD Price Performance: -19.89%
Average Trading Volume: 4,525
Technical Sentiment Signal: Buy
Current Market Cap: $1.95M
Find detailed analytics on VCNX stock on TipRanks’ Stock Analysis page.